Literature DB >> 17961767

Counterselection of prokaryotic ribosomal RNA during reverse transcription using non-random hexameric oligonucleotides.

J M Gonzalez1, F T Robb.   

Abstract

Ribosomal RNA (rRNA) is the major component in total RNA extracts, interfering with the synthesis of cDNA corresponding to messenger RNA (mRNA). In this study, we present a novel strategy for selectively discriminating against rRNA and favoring mRNA from prokaryotes during synthesis of cDNA by reverse transcriptase. Our technique is based on the fact that rRNA sequences, in many species, are G+C rich relative to the genome at large, and highly conserved among prokaryotes. The sequence TTTT is therefore rarely found in rRNA sequences. However, TTTT priming sites are found at a much higher frequency in protein-encoding gene sequences. We designed specific hexamers (HD/DHTTTT) to prime reverse transcription reactions resulting in a selective synthesis of cDNA corresponding to mRNA from prokaryotic total RNA extractions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961767     DOI: 10.1016/j.mimet.2007.09.010

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN: 0167-7012            Impact factor:   2.363


  3 in total

1.  LOX: inferring Level Of eXpression from diverse methods of census sequencing.

Authors:  Zhang Zhang; Francesc López-Giráldez; Jeffrey P Townsend
Journal:  Bioinformatics       Date:  2010-06-10       Impact factor: 6.937

2.  Digital transcriptome profiling using selective hexamer priming for cDNA synthesis.

Authors:  Christopher D Armour; John C Castle; Ronghua Chen; Tomas Babak; Patrick Loerch; Stuart Jackson; Jyoti K Shah; John Dey; Carol A Rohl; Jason M Johnson; Christopher K Raymond
Journal:  Nat Methods       Date:  2009-08-09       Impact factor: 28.547

3.  Multi-targeted priming for genome-wide gene expression assays.

Authors:  Aleksandra B Adomas; Francesc Lopez-Giraldez; Travis A Clark; Zheng Wang; Jeffrey P Townsend
Journal:  BMC Genomics       Date:  2010-08-17       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.